Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.
Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.
Contributors: Dr. Adrian Lau, Dr. Heather McDonald-Blumer, Dr. Sandra Kim, Dr. Natasha Gakhal, Dr. Lianne Tile, Dr. Angela Cheung, Dr. Julie Gilmour, Dr. Laëtitia Michou, Dr. Claudia Gagnon, Dr. Zahra […]
FDA Qualifies First Surrogate Endpoint For Use In Osteoporosis Clinical Trials
December 22, 2025
Update On Clinical Trials FDA Qualifies First Surrogate Endpoint For Use In Osteoporosis Clinical Trials December 22, 2025 Osteoporosis Canada is excited to share the US Food and Drug Administration […]
World Health Organization (WHO) publishes article on benchmarks for equitable hip-fracture care and osteoporosis treatment in older people
December 9, 2025
Latest News World Health Organization (WHO) publishes article on benchmarks for equitable hip-fracture care and osteoporosis treatment in older people December 9, 2025 In Canada, one in three hip fracture […]
